UNSPSC 51241508: Benzalkonium/calcium chloride/hydrochloric acid/magnesium chloride

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP500. This VA Drug Class (OP500) classifies this compound as belonging to the group EYE WASHES/LUBRICANTS.

UNSPSC 51241508 Benzalkonium/calcium chloride/hydrochloric acid/magnesium chloride is a Commodity code under which state and local governments procure active pharmaceutical ingredients and chemical compounds used in over-the-counter products, topical disinfectants, and electrolyte formulations. The scope includes supply of bulk or finished pharmaceutical-grade chemical products that meet FDA requirements and current Good Manufacturing Practices (cGMP), with vendors required to provide detailed product specifications including National Drug Codes (NDC), strengths, dosage forms, packaging configurations, and manufacturing locations. Issuing bodies include state cooperative purchasing alliances, state departments of health and human services, and participating municipalities and county health agencies that source through multistate purchasing vehicles. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary recent buyer in this category, managing procurement on behalf of multiple state and local government facilities across participating jurisdictions including Minnesota and Oregon.

MMCAP issued a Request for Proposal (S1070000015802) on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products, with proposals due March 26, 2026. The solicitation requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and emphasizes price competitiveness (75 percent of evaluation weight) alongside compliance with EDI capability, administrative fee format requirements, and cGMP and Drug Supply Chain Security Act (DSCSA) certification. Vendors must maintain relationships with at least two of the three authorized wholesalers with chargeback systems in place and provide pricing flexibility through flat-price, net-price, or WAC-minus structures. The contract term is two years with optional extensions at MMCAP's discretion; awarded vendors will supply products effective July 1, 2026.